Cargando…

Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model

BACKGROUND: Intra-arterial (IA) administration of rt-PA for ischemic stroke has the potential for greater thrombolytic efficacy, especially for a large thrombus in the M1 or M2 segment of the middle cerebral artery (MCA). Intracranial hemorrhage (ICH) is a concern with IA or intravenous (IV) adminis...

Descripción completa

Detalles Bibliográficos
Autores principales: Crumrine, R Christian, Marder, Victor J, Taylor, G McLeod, LaManna, Joseph C, Tsipis, Constantinos P, Scuderi, Philip, Petteway, Stephen R, Arora, Vikram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184064/
https://www.ncbi.nlm.nih.gov/pubmed/21933438
http://dx.doi.org/10.1186/2040-7378-3-10
_version_ 1782213050896482304
author Crumrine, R Christian
Marder, Victor J
Taylor, G McLeod
LaManna, Joseph C
Tsipis, Constantinos P
Scuderi, Philip
Petteway, Stephen R
Arora, Vikram
author_facet Crumrine, R Christian
Marder, Victor J
Taylor, G McLeod
LaManna, Joseph C
Tsipis, Constantinos P
Scuderi, Philip
Petteway, Stephen R
Arora, Vikram
author_sort Crumrine, R Christian
collection PubMed
description BACKGROUND: Intra-arterial (IA) administration of rt-PA for ischemic stroke has the potential for greater thrombolytic efficacy, especially for a large thrombus in the M1 or M2 segment of the middle cerebral artery (MCA). Intracranial hemorrhage (ICH) is a concern with IA or intravenous (IV) administration especially as the therapeutic window is extended. However, because IA administration delivers a higher local concentration of agent, the incidence and severity of ICH may be greater than with similar doses IV. We investigated the safety of rt-PA administration by IA compared to IV infusion following 6 hours of MCA occlusion (MCAo) with reflow in the spontaneously hypertensive rat (SHR). METHODS: Male SHRs were subjected to 6 hours MCAo with 18 hours reflow using a snare ligature model. They were treated with IA saline, IA rt-PA (1, 5, 10, 30 mg/kg), or IV rt-PA (10 and 30 mg/kg) by a 10 to 60 minute infusion beginning approximately 1 minute before reflow. The rats were recovered for 24 hours after MCAo onset at which time Bleeding Score, infarct volume, and Modified Bederson Score were measured. RESULTS: Greater hemorrhagic transformation occurred with 10 and 30 mg/kg rt-PA administered IA than IV. The IV 10 mg/kg rt-PA dosage induced significantly less bleeding than did the 1 or 5 mg/kg IA groups. No significant increase in infarct volume was observed after IA or IV treatment. Rats treated with 30 mg/kg rt-PA by either the IA or IV route had greater neurological dysfunction compared to all other groups. CONCLUSIONS: Administration of rt-PA by the IA route following 6 hours of MCAo results in greater ICH and worse functional recovery than comparable dosages IV. Significantly greater bleeding was observed when the IA dose was a tenth of the IV dose. The increased bleeding did not translate in larger infarct volumes.
format Online
Article
Text
id pubmed-3184064
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31840642011-10-01 Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model Crumrine, R Christian Marder, Victor J Taylor, G McLeod LaManna, Joseph C Tsipis, Constantinos P Scuderi, Philip Petteway, Stephen R Arora, Vikram Exp Transl Stroke Med Research BACKGROUND: Intra-arterial (IA) administration of rt-PA for ischemic stroke has the potential for greater thrombolytic efficacy, especially for a large thrombus in the M1 or M2 segment of the middle cerebral artery (MCA). Intracranial hemorrhage (ICH) is a concern with IA or intravenous (IV) administration especially as the therapeutic window is extended. However, because IA administration delivers a higher local concentration of agent, the incidence and severity of ICH may be greater than with similar doses IV. We investigated the safety of rt-PA administration by IA compared to IV infusion following 6 hours of MCA occlusion (MCAo) with reflow in the spontaneously hypertensive rat (SHR). METHODS: Male SHRs were subjected to 6 hours MCAo with 18 hours reflow using a snare ligature model. They were treated with IA saline, IA rt-PA (1, 5, 10, 30 mg/kg), or IV rt-PA (10 and 30 mg/kg) by a 10 to 60 minute infusion beginning approximately 1 minute before reflow. The rats were recovered for 24 hours after MCAo onset at which time Bleeding Score, infarct volume, and Modified Bederson Score were measured. RESULTS: Greater hemorrhagic transformation occurred with 10 and 30 mg/kg rt-PA administered IA than IV. The IV 10 mg/kg rt-PA dosage induced significantly less bleeding than did the 1 or 5 mg/kg IA groups. No significant increase in infarct volume was observed after IA or IV treatment. Rats treated with 30 mg/kg rt-PA by either the IA or IV route had greater neurological dysfunction compared to all other groups. CONCLUSIONS: Administration of rt-PA by the IA route following 6 hours of MCAo results in greater ICH and worse functional recovery than comparable dosages IV. Significantly greater bleeding was observed when the IA dose was a tenth of the IV dose. The increased bleeding did not translate in larger infarct volumes. BioMed Central 2011-09-20 /pmc/articles/PMC3184064/ /pubmed/21933438 http://dx.doi.org/10.1186/2040-7378-3-10 Text en Copyright ©2011 Crumrine et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Crumrine, R Christian
Marder, Victor J
Taylor, G McLeod
LaManna, Joseph C
Tsipis, Constantinos P
Scuderi, Philip
Petteway, Stephen R
Arora, Vikram
Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model
title Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model
title_full Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model
title_fullStr Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model
title_full_unstemmed Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model
title_short Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model
title_sort intra-arterial administration of recombinant tissue-type plasminogen activator (rt-pa) causes more intracranial bleeding than does intravenous rt-pa in a transient rat middle cerebral artery occlusion model
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3184064/
https://www.ncbi.nlm.nih.gov/pubmed/21933438
http://dx.doi.org/10.1186/2040-7378-3-10
work_keys_str_mv AT crumrinerchristian intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel
AT mardervictorj intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel
AT taylorgmcleod intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel
AT lamannajosephc intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel
AT tsipisconstantinosp intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel
AT scuderiphilip intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel
AT pettewaystephenr intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel
AT aroravikram intraarterialadministrationofrecombinanttissuetypeplasminogenactivatorrtpacausesmoreintracranialbleedingthandoesintravenousrtpainatransientratmiddlecerebralarteryocclusionmodel